Tarceva (erlotinib HCl, OSI-774 )
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-small-cell Lung
Conditions
Carcinoma, Non-small-cell Lung
Trial Timeline
Nov 1, 2001 โ Jan 30, 2004
NCT ID
NCT00036647About Tarceva (erlotinib HCl, OSI-774 )
Tarceva (erlotinib HCl, OSI-774 ) is a phase 3 stage product being developed by Astellas Pharma for Carcinoma, Non-small-cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00036647. Target conditions include Carcinoma, Non-small-cell Lung.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00036647 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Non-small-cell Lung